冠状动脉血管生成的机制及治疗分子靶点研究进展  

Research progress on the mechanism of coronary angiogenesis and therapeutic molecular targets

作　　者：顾宁越(综述) 张艳达(综述) 梁春(审校)[1] Gu Ningyue;Zhang Yanda;Liang Chun(Department of Cardiology, Shanghai Changzhen Hospital, Second Military Medical University, Shanghai 200003, China)

机构地区：[1]第二军医大学附属长征医院心内科,上海200003

出　　处：《疑难病杂志》2021年第6期627-630,635,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金资助项目(81473445,91539118,81611130092);上海市科学技术委员会优秀学术带头人计划(17XD1405000);上海市医学领军人才计划(LJRC2015-21);上海市中西医临床协作试点项目(ZY2018-2020-FWTX-1102)。

摘　　要：冠心病(CAD)是发达国家人口死亡的主要病因之一。遗传易感性和环境因素导致了冠状动脉管壁动脉粥样硬化斑块的进展,引起心肌灌注减少。药物治疗和冠状动脉血运重建术的进步极大地改善了冠心病患者的预后。但是对于部分无法再血管化的严重冠心病患者,治疗性血管新生成为改善心肌缺血最有希望的方法。然而,在冠状动脉粥样硬化斑块进展阶段病理性的血管新生也曾作为冠心病治疗的靶点。促进或抑制血管新生需要从不同的时间窗着手。文章综述冠心病血管新生的机制,以及对治疗性冠状动脉血管生成的分子靶点进行探索。Coronary heart disease(CAD)is one of the main causes of death in developed countries.Genetic susceptibility and environmental factors have led to the progression of atherosclerotic plaques on the walls of coronary arteries,resulting in decreased myocardial perfusion.Advances in drug therapy and coronary revascularization have greatly improved the prognosis of patients with coronary heart disease.However,for some patients with severe coronary heart disease who cannot be revascularized,therapeutic angiogenesis has become the most promising method to improve myocardial ischemia.However,pathological angiogenesis in the advanced stage of coronary atherosclerotic plaque has also been used as a target for the treatment of coronary heart disease.Promoting or inhibiting angiogenesis needs to start from different time windows.This article reviews the mechanism of coronary angiogenesis in coronary heart disease,and explores the molecular targets of therapeutic coronary angiogenesis.

关 键 词：冠心病 血管新生 心肌缺血 分子靶点 

分 类 号：R541.4[医药卫生—心血管疾病]